Tags

Type your tag names separated by a space and hit enter

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
J Virol. 2015 Aug; 89(16):8651-6.JV

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8(+) T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.

Authors+Show Affiliations

German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany.German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany.German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany.German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany.German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.University of Giessen Lung Center, Department of Internal Medicine II, Section of Infectious Diseases, Giessen, Germany.German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany gerd.sutter@lmu.de.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26018172

Citation

Volz, Asisa, et al. "Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein." Journal of Virology, vol. 89, no. 16, 2015, pp. 8651-6.
Volz A, Kupke A, Song F, et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J Virol. 2015;89(16):8651-6.
Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., Schmidt, J., Becker, C., Eickmann, M., Becker, S., & Sutter, G. (2015). Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. Journal of Virology, 89(16), 8651-6. https://doi.org/10.1128/JVI.00614-15
Volz A, et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J Virol. 2015;89(16):8651-6. PubMed PMID: 26018172.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. AU - Volz,Asisa, AU - Kupke,Alexandra, AU - Song,Fei, AU - Jany,Sylvia, AU - Fux,Robert, AU - Shams-Eldin,Hosam, AU - Schmidt,Jörg, AU - Becker,Christin, AU - Eickmann,Markus, AU - Becker,Stephan, AU - Sutter,Gerd, Y1 - 2015/05/27/ PY - 2015/03/05/received PY - 2015/05/23/accepted PY - 2015/5/29/entrez PY - 2015/5/29/pubmed PY - 2016/1/23/medline SP - 8651 EP - 6 JF - Journal of virology JO - J Virol VL - 89 IS - 16 N2 - Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8(+) T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine. SN - 1098-5514 UR - https://www.unboundmedicine.com/medline/citation/26018172/Protective_Efficacy_of_Recombinant_Modified_Vaccinia_Virus_Ankara_Delivering_Middle_East_Respiratory_Syndrome_Coronavirus_Spike_Glycoprotein_ L2 - http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=26018172 DB - PRIME DP - Unbound Medicine ER -